The FDA says the shortage of popular weight loss drug Zepbound is over. Here's what that means for patients.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to cheaper versions could end.
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
The FDA says the Zepbound shortage is over. That's rattling the weight loss industry
The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli Lilly’s (LLY) popular diabetes and weight-loss drugs Mounjaro and Zepbound — is officially over.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.
FDA approves weight loss drug Zepbound to treat obstructive sleep apnea
The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
Weight Loss Drug Tirzepatide Now Approved for Sleep Apnea in Adults With Obesity
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.
Weight loss drug Zepbound gets US FDA nod to treat sleep apnea; India launch expected in 2025
In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known as Tirzepatide, for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
‘An insatiable itch’: Why some people are turning to weight-loss medications to help quiet food noise
Savannah Mendoza used to spend most of her paychecks on food delivery apps and at fast food drive-thrus, trying to satisfy a ...
ABC News22d
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Tirzepatide, used in Zepbound and Mounjaro ... the idea that dual mechanisms of action will producer greater weight loss," Aronne, also the Sanford I. Weill Professor of Metabolic Research ...
Medical News Today16d
Average weight loss on Zepbound
Research consistently suggests people with overweight or obesity have more average weight loss on Zepbound than a placebo. The active ingredient in Zepbound is tirzepatide, which falls into ...
KETV Omaha3d
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
Treatment with Zepbound, whose generic name is tirzepatide, led to improvements ... That equates to 45 to 50 pounds of weight loss, on average, over a year, Lilly said. Patients on the drug ...